Low blood sugar Hypoglycemia is a greater concern when these medications are used with insulin or medicines that increase insulin secretion, such as sulfonylureas
Here is how many participants in each group hit specific milestones: 10% or more body weight loss: More participants achieved this with tirzepatide 15% or more body weight loss: Substantially more with tirzepatide 20% or more body weight loss: Significantly more with tirzepatide 25% or more body weight loss: 31.6% of tirzepatide users versus only 16.1% of semaglutide users Nearly twice as many people on tirzepatide achieved 25% or greater body weight loss compared to semaglutide
Bakery Items: Donuts, pastries, cakes, muffins
This study aims to investigate whether semaglutide can reduce the progression of noncalcified coronary atherosclerotic plaque volume, as measured by serial coronary computed tomography angiography (CTA), over a one-year period compared to a placebo, in individuals with diabetes
When used with insulin or sulfonylureas, semaglutide increases the risk of hypoglycemia
